97029 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Receptors; Cell surface antigens; Cell surface determinants Immunoglobulin superfamily
SIRP-ALPHA VARIANT CONSTRUCTS AND USES THEREOF
#902Multipartite signaling proteins and uses thereof
#903Methods for inhibiting HIV or HCV infection by administering TIM-3 binding inhibitors
#904TUMOR ANTIGEN PEPTIDE
#905Combined preparations for the treatment of cancer
#906POLYPEPTIDES AND USES THEREOF FOR TREATMENT OF AUTOIMMUNE DISORDERS AND INFECTION
#907Cell
#908Cell
#909CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
#910Reducing immune tolerance induced by PD-L1
#911COMPOSITIONS AND METHODS FOR CANCER TREATMENT
#912Fusion polypeptides comprising mucin-domain polypeptide linkers
#913Soluble CD33 for treating myelodysplastic syndromes (MDS)
#914EPITOPE VACCINE FOR LOW IMMUNOGENIC PROTEIN AND PREPARING METHOD AND USAGE THEREOF
#915Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer
#916SIRP-ALPHA VARIANT CONSTRUCTS AND USES THEREOF
#917Engineered γδ T-cells
#918METHODS FOR CONTROLLED ELIMINATION OF THERAPEUTIC CELLS
#919System for immunotherapy targeting tumor propagation and progression
#920Identification of VSIG8 as the putative VISTA receptor (V-R) and use thereof to produce VISTA/VSIG8 agonists and antagonists
#921Coiled coil immunoglobulin fusion proteins and compositions thereof
#922Compositions and methods for treatment of non-hodgkins lymphoma
#923Non-human animals having a humanized cluster of differentiation 47 gene
#924ILT3 polypeptides and uses thereof
#925Methods for treatment comprising an antibody that binds CD223 protein
#926Anti-CD19 scFv (FMC63) polypeptide
#927Replication defective adenovirus vector in vaccination
#928Methods and compositions relating to improved lentiviral vectors and their applications
#929PD-1 antibodies
#930High affinity PD-1 agents and methods of use
#931Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
#932Non-human animals having a humanized signal-regulatory protein gene
#933High affinity PD-1 agents and methods of use
#934MODIFIED FC FUSION PROTEINS
#935TIM RECEPTORS AS VIRUS ENTRY COFACTORS
#936Inhibiting peptides derived from TREM-like transcript 1 (TLT-1) and uses thereof
#937Methods and compositions for inhibiting the effects of amyloid beta oligomers
#938Compositions and methods to improve adoptive cell therapies
#939CD31 peptides for the treatment of thrombotic or autoimmune disorders
#940A SELECTIVE HIGH-AFFINITY IMMUNE STIMULATORY REAGENT AND USES THEREOF
#941Nucleic acids encoding rage fusion proteins
#942Non-human animals having a humanized programmed cell death 1 gene
#943High avidity antigen recognizing constructs
#944Myelin oligodendrocyte glycoprotein peptides
#945BTNL9 proteins, nucleic acids, and antibodies and uses thereof
#946Compositions and methods for immunotherapy
#947Diagnostic, prognostic, therapeutic and screening protocols
#948Treatment of CD47+ disease cells with SIRP alpha-Fc fusions
#949Chimeric antigen receptors
#950PEPTIDIC ANTAGONISTS OF CLASS III SEMAPHORINS/NEUROPILINS COMPLEXES
#951Medicament comprising activity modulator for CD300a-expressing cell associated with allergic disease, CD300a gene-deficient mouse, and use of activity modulator for CD300a-expressing cell
#952Methods and compositions for modulating Toso activity
#953Compositions and methods for inhibiting viral entry
#954THY1 (CD90) as a novel therapy to control adipose tissue accumulation
#955Multipartite signaling proteins and uses thereof
#956Anti-MCAM Antibodies and Associated Methods of Use
#957CD47 antibodies and methods of use thereof
#958Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (TREM-1) TREM-like transcript 1 (TLT-1) for treatment of cardiovascular diseases
#959Modulation of the immune response
#960METHODS OF TREATMENT USING FUSION PROTEINS
#961Methods and compositions for modulating Toso activity
#962ENGINEERING T CELL RECEPTORS
#963Methods of treating metabolic disease
#964Composition for preventing or treating fracture or osteoporosis using slit-robo system
#965Modulation of immunity and CEACAM1 activity
#966CEACAM1 mediated protective immunity
#967Methods and compositions for modulating toso activity
#968Dendrimer conjugates for coating cells
#969Antimicrobial peptide and use thereof
#970Immunomodulating cyclic compounds
#971Methods for treating muscle specific receptor kinase (MuSK) myasthenia gravis with the Ig1 domain of MuSK
#972LINGO-2 antagonists for treatment of conditions involving motor neurons
#973CD147 as receptor for pilus-mediated adhesion of to vascular endothelia
#974NKP30 receptor targeted therapeutics
#975Marker-suicide gene useful in adoptive cell therapy
#976Non-human animals having a humanized signal-regulatory protein gene
#977Non-human animals having a humanized signal-regulatory protein gene
#978HIV vpr-specific T-cell receptors
#979METHODS OF MODULATING IMMUNE RESPONSES BY MODULATING TIM-1, TIM-2 AND TIM-4 FUNCTION
#980CELL-BASED ANTI-CANCER COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
#981Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases
#982Detection of platelet-derived shed CD31
#983Transgenic immunodeficient mouse expressing human SIRP-alpha
#984Chimeric antigen receptors targeting B-cell maturation antigen
#985Human soluble receptor for advanced glycation end products (sRAGE), methods of preparing human sRAGE, and treatment methods using sRAGE
#986FAS-chimera adenovirus vector
#987ROBO2 inhibitory compositions comprising SLIT2-binding extracellular domain of ROBO2
#988Modulation of TIM receptor activity in combination with cytoreductive therapy
#989Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
#990Use of ICOS-based CARs to enhance antitumor activity and CAR persistence
#991METHODS AND COMPOSITIONS FOR INHIBITION OF IMMUNE RESPONSES
#992T CELL RECEPTORS RECOGNIZING HLA-A1- OR HLA-CW7-RESTRICTED MAGE
#993Molecules with extended half-lives, compositions and uses thereof
#994FUSION PROTEINS COMPRISING IGG2 HINGE DOMAINS
#995Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
#996TIM-3 ligands and methods of modulating immune responses
#997Soluble CD27 (sCD27) and the use thereof
#998Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
#999Antibodies against novel PD1 isoforms and uses thereof
#1000Treatment of cancer using humanized anti-CD19 chimeric antigen receptor
#1001Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
#1002Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
#1003Ligands modified by circular permutation as agonists and antagonists
#1004Inhibition of innate immune response
#1005Methods and compositions relating to improved lentiviral vectors and their applications
#1006Novel VISTA-Ig constructs and the use of VISTA-Ig for Treatment of Autoimmune, Allergic and Inflammatory Disorders
#1007Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
#1008GP100-specific T cell receptors and related materials and methods of use
#1009Switch costimulatory receptors
#1010T cell receptors and related materials and methods of use
#1011Polypeptides and uses thereof for treatment of autoimmune disorders and infection
#1012PROBE FOR DETECTING DEAD CELL
#1013F11 receptor (F11R) antagonists as therapeutic agents
#1014Inhibition of TREM receptor signaling with peptide variants
#1015Compounds for treating cardiac damage after ischaemia/reperfusion
#1016Soluble hybrid Fcγ receptors and related methods
#1017Thymidylate kinase fusions and uses thereof
#1018ANTI-CD147 ANTIBODIES, METHODS AND USES
#1019Affinity maturated T cell receptors and use thereof
#1020VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
#1021Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
#1022Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer
#1023Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
#1024Fusion polypeptides comprising mucin-domain polypeptide linkers
#1025Ligands modified by circular permutation as agonists and antagonists
#1026Therapeutic and diagnostic cloned MHC-unrestricted receptor specific for the MUC1 tumor associated antigen
#1027Method of treating type 1 diabetes by administering NKp46 polypeptide
#1028Antigen-specific T cell receptors and T cell epitopes
#1029System for immunotherapy targeting tumor propagation and progression
#1030Anti-CEACAM6 antibodies and uses thereof
#1031Biomarkers associated with nephropathy
#1032Compositions and methods for the treatment of immune related diseases
#1033CD47 antibodies and methods of use thereof
#1034Sequential administration of a replication defective adenovirus vector in vaccination protocols
#1035T cell receptors and related materials and methods of use
#1036Methods of treatment using rage fusion proteins
#1037Vista regulatory T cell mediator protein, vista binding agents and use thereof
#1038NCAM-VASE AND NEURODEGENERATION
#1039Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
#1040T CELL RECEPTOR MUTANTS
#1041RAGE Fusion Protein Compositions And Methods Of Use
#1042Methods and compositions relating to improved lentiviral vectors and their applications
#1043NOVEL GLYCOSYLATED PEPTIDE TARGET IN NEOPLASTIC CELLS
#1044Method for treating cancer with an antibody to CD223 protein
#1045Molecules with extended half-lives, compositions and uses thereof
#1046Inhibiting collagen-induced platelet aggregation and activation with peptide variants
#1047ISOLATED MAMMALIAN MONOCYTE CELL GENES; RELATED REAGENTS
#1048Inhibiting peptides derived from TREM-like transcript 1 (TLT-1) and uses thereof
#1049NOVEL RECEPTOR TREM (TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS) AND USES THEREOF
#1050MUCOSAL VASCULAR ADDRESSINS AND USES THEREOF
#1051Peptide analogues
#1052SOLUBLE PROTEINS FOR USE AS THERAPEUTICS
#1053Chimpanzee adenovirus vaccine carriers
#1054ILT3 polypeptides and uses thereof
#1055Monomeric Bi-Specific Fusion Protein
#1056TRANSGENIC MICE OVER-EXPRESSING RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCT (RAGE) IN BRAIN AND USES THEREOF
#1057NOVEL GENES ENCODING PROTEINS HAVING PROGNOSTIC, DIAGNOSTIC, PREVENTIVE, THERAPEUTIC, AND OTHER USES
#1058Multimer of extracellular domain of cell surface functional molecule
#1059Methods of using BTL-II proteins
#1060MODULATED PROGRAMMED DEATH LIGAND-1
#1061CELL-BASED ANTI-CANCER COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
#1062GP100-specific T cell receptors and related materials and methods of use
#1063FUNCTIONALIZED CELL BINDING PEPTIDES AND CELL CULTURE ARTICLES
#1064Inhibition of TREM receptor signaling with peptide variants
#1065Compositions and methods for treatment of cervical dysplasia
#1066Modulation of TIM receptor activity in combination with cytoreductive therapy
#1067Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
#1068Compositions and methods for treatment of cancer
#1069Crystal of Human Glycoprotein VI Collagen Binding Domain
#1070Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
#1071Repertoire of allo-restricted peptide-specific T cell receptor sequences and use thereof
#1072Pancreatic cancer targets and uses thereof
#1073Signature Of Secreted Protein Isoforms Specific To Ovarian Cancer
#1074SUGAR CHAIN-ADDED AILIM EXTRACELLULAR DOMAIN AND METHOD FOR PRODUCING SAME
#1075Method of treating diabetes by administering an anti-NKp46 antibody
#1076Method For Detecting And Purifying Pancreatic Beta Cells
#1077Therapeutic use of anti-CS1 antibodies
#1078Therapeutic use of anti-CS1 antibodies
#1079Therapeutic use of anti-CS1 antibodies
#1080Therapeutic use of anti-CS1 antibodies
#1081Control of RAGE fusion protein glycosylation and RAGE fusion protein compositions
#1082Methods of treating disorders by administration of F11 receptor antagonists
#1083T cell receptor mutants
#1084ISOLATED MAMMALIAN MONOCYTE CELL GENES; RELATED REAGENTS
#1085Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases
#1086T cell receptors and related materials and methods of use
#1087Therapeutic TREM-1 peptides
#1088CD31 peptides in the treatment of thrombotic and autoimmune disorders
#1089Monocyte-derived nucleic acids and related compositions and methods
#1090Molecules with extended half-lives, compositions and uses thereof
#1091Inhibitors of myelin-associated glycoprotein (MAG) activity for regulating neural growth and regeneration
#1092NECTIN-4 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS
#1093Human soluble CD146, preparation and uses thereof
#1094Nucleic acid molecules encoding rage fusion proteins
#1095Transgenic Aves Producing Human Polyclonal Antibodies
#1096Methods of determining susceptibility of tumors to tyrosine kinase inhibitors
#1097METHODS AND MATERIALS RELATING TO CD84-LIKE POLYPEPTIDES AND POLYNUCLEOTIDES
#1098Compositions and methods for inhibiting vascular permeability
#1099Recombinant platelet collagen receptor glycoprotein VI and its pharmaceutical use
#1100PD-1 antibodies
#1101Chimpanzee adenovirus vaccine carriers
#1102Soluble hybrid Fcγ receptors and related methods
#1103Epitope of CD66C specific to lung adenocarcinoma and antibody recognizing the same
#1104METHODS AND COMPOSITIONS FOR MODULATING IMMUNITY
#1105Anti-CD147 antibodies, methods and uses
#1106METHODS AND COMPOSITIONS FOR MANIPULATING THE GUIDED NAVIGATION OF ENDOTHELIAL TUBES DURING ANGIOGENESIS
#1107Use of agents derived from CEACAM1 for the treatment of inflammatory diseases
#1108Fiducial markers for augmented reality
#1109MINIGENE
#1110Immunoglobulin chimeric monomer-dimer hybrids
#1111NOVEL SOLUBLE CD83 POLYPEPTIDES, FORMULATIONS AND METHODS OF USE
#1112ILT-2 (LIR1) VARIANTS WITH INCREASED AFFINITY FOR MHC CLASS I MOLECULES
#1113Immunogenic peptides
#1114Methods for Chemically Synthesizing Immunoglobulin Chimeric Proteins
#1115Polynucleotides and Polypeptides Encoding Receptors
#1116Manipulation of Cytokine Levels Using CD83 Gene Products
#1117Methods of treating cancer by administering antibodies to CD200
#1118Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) in brain and uses thereof
#1119Use of LINGO-4 Antagonists in the Treatment of Conditions Involving Demyelination
#1120Optimized adhesin fragments and corresponding nanoparticles
#1121Thymidylate kinase fusions and uses thereof
#1122T cell receptors and related materials and methods of use
#1123Immunotherapy for Unresectable Pancreatic Cancer
#1124Peptides derived from NCAM (FGLs)
#1125THERAPEUTIC AND DIAGNOSTIC AGENTS
#1126Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
#1127BIOMARKERS ASSOCIATED WITH NEPHROPATHY
#1128Receptor-Based Blood Detoxification System
#1129Biomarkers associated with nephropathy
#1130BIOMARKERS ASSOCIATED WITH NEPHROPATHY
#1131Chimeric antigen-specific T cell-activating polypeptides
#1132DENDRITIC CELL POTENTIATION
#1133Compositions and Methods for Treatment of Neoplastic Disease
#1134METHODS OF MODULATING IMMUNE RESPONSES BY MODULATING TIM-1, TIM-2 AND TIM-4 FUNCTION
#1135Ilt3 Binding Molecules And Uses Therefor
#1136Use of modified cells for the treatment of multiple sclerosis
#1137Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
#1138Compositions and Methods for Cancer Treatment
#1139Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response
#1140Method of identifying a compound for preventing and/or treating an autoimmune disease
#1141Methods of using BTL-II proteins
#1142Crystal of human glycoprotein VI collagen binding domain
#1143HLA-DR BINDING PEPTIDES AND THEIR USES
#1144Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
#1145NOVEL RECEPTOR TREM (TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS) AND USES THEREOF
#1146PEPTIDE ANALOGUES
#1147HIV VPR-specific T cell receptors
#1148Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
#1149Polypeptides, cyclic polypeptides and pharmaceutical comprising thereof for non invasive specific imaging of fibrosis
#1150Soluble GP130 muteins with improved binding activity
#1151ANTIBODIES TO IREM-1
#1152Rage fusion proteins
#1153Vascular adhesion molecules and modulation of their function
#1154Monocyte-derived nucleic acids and related compositions and methods
#1155Novel co-stimulatory molecules
#1156Method for treating symptoms of diabetes
#1157Methods of inhibiting viral replication and improving T cell function employing soluble Tim-3 inhibitors
#1158IDENTIFICATION OF NEW ISOFORMS OF THE MHC-CLASS I SPECIFIC RECEPTOR CD160 AND USES THEREOF
#1159Peptidic antagonists of class III semaphorins/neuropilins complexes
#1160METHODS OF TREATMENT USING LDCAM
#1161BIOMARKERS ASSOCIATED WITH NEPHROPATHY
#1162Antibodies that bind DNAX leukocyte associated immunoglobulin-like receptor
#1163AGONIST AND ANTAGONIST PEPTIDES OF CARCINOEMBRYONIC ANTIGEN (CEA)
#1164Polypeptides or fusion proteins thereof inhibiting transmigration of leucocytes or growth and/or metastasis of cancer cells
#1165Anti-cancer vaccine composition comprising an anti-CD223 antibody and kit comprising an anti-cancer vaccine and an anti-CD223 antibody
#1166Pharmaceutical composition for treating cholangiocarcinoma, a method for inhibiting growth or invasion of cholangiocarcinoma and a method for treating cholangiocarcinoma
#1167Molecules with extended half-lives, compositions and uses thereof
#1168Sequential administration of a replication defective adenovirus vector in vaccination protocols
#1169REGULATION OF MYELINATION BY NECTIN-LIKE (NECL) MOLECULES
#1170Affinity matured CRIg variants
#1171POLYPEPTIDE MONOMERS AND DIMERS CONTAINING MUTATED ILT
#1172Mammalian Cell Membrane Proteins; Related Reagents
#1173Manipulation of cytokine levels using CD83 gene products
#1174LIR-9, a novel leukocyte immunoglobulin-like receptor
#1175KIM-1 ANTAGONISTS AND USE TO MODULATE IMMUNE SYSTEM
#1176Biological Materials and Uses Thereof
#1177Compositions and methods for treating ocular pathologic angiogenesis and vascular permeability
#1178Methods and compositions relating to improved lentiviral vectors and their applications
#1179Method for Removal or Inactivation of Heparin
#1180DENDRITIC CELL POTENTIATION
#1181Novel Triggering Receptor Involved in Natural Cytotoxicity Mediated by Human Natural Killer Cells and Antibodies That Identify the Same
#1182GP100-specific T cell receptors and related materials and methods of use
#1183DENDRITIC CELL POTENTIATION
#1184AGENT FOR PREVENTING/TREATING CANCER
#1185Antibodies which bind to epitopes of glycoprotein VI
#1186Immunomodulation
#118712 human secreted proteins
#1188Compounds capable of affecting differentiation, proliferation, regeneration, plasticity and survival cells
#1189Multimer of extracellular domain of cell surface functional molecule
#1190Mast Cell-Derived Membrane Proteins
#1191ILT3 polypeptides and uses thereof
#1192MAMMALIAN CELL MEMBRANE PROTEINS; RELATED REAGENTS
#1193Pituitary adenylate cyclase activating peptide (PACAP) receptor (VPAC2) agonists and their pharmacological methods of use
#1194NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES
#1195Therapeutic peptides and method
#1196T Cell Regulatory Genes And Methods Of Use Thereof
#1197Therapeutic use of anti-CS1 antibodies
#1198THERAPEUTIC AND DIAGNOSTIC AGENTS
#1199Methods and compositions for modulating immunity
#1200BIVM (BASIC, IMMUNOGLOBULIN-LIKE VARIABLE MOTIF-CONTAINING) GENE, TRANSCRIPTIONAL PRODUCTS, AND USES THEREOF